These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11728495)

  • 1. First trimester Down Syndrome screening by nuchal translucency in a Thai population.
    Panburana P; Ajjimakorn S; Tungkajiwangoon P
    Int J Gynaecol Obstet; 2001 Dec; 75(3):311-2. PubMed ID: 11728495
    [No Abstract]   [Full Text] [Related]  

  • 2. First trimester nuchal translucency: effective routine screening for Down's syndrome.
    Thilaganathan B; Sairam S; Michailidis G; Wathen NC
    Br J Radiol; 1999 Oct; 72(862):946-8. PubMed ID: 10673944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history of trisomy 21 fetuses with increased nuchal translucency thickness.
    Pandya PP; Snijders RJ; Johnson S; Nicolaides KH
    Ultrasound Obstet Gynecol; 1995 Jun; 5(6):381-3. PubMed ID: 7552798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome.
    Thilaganathan B; Slack A; Wathen NC
    Ultrasound Obstet Gynecol; 1997 Oct; 10(4):261-4. PubMed ID: 9383877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down's syndrome screening with nuchal translucency.
    Hackshaw AK; Wald NJ; Haddow JE
    Lancet; 1996 Dec 21-28; 348(9043):1740. PubMed ID: 8973459
    [No Abstract]   [Full Text] [Related]  

  • 6. First-trimester screening for aneuploidy with fetal nuchal translucency in a United States population.
    Chasen ST; Sharma G; Kalish RB; Chervenak FA
    Ultrasound Obstet Gynecol; 2003 Aug; 22(2):149-51. PubMed ID: 12905508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
    Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
    Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for nuchal translucency: expect or expedite?
    Herman A; Dreazen E
    Ultrasound Obstet Gynecol; 1996 Aug; 8(2):138. PubMed ID: 8883321
    [No Abstract]   [Full Text] [Related]  

  • 10. Fetal nuchal translucency: ultrasound screening for fetal trisomy in the first trimester of pregnancy.
    Nicolaides KH; Brizot ML; Snijders RJ
    Br J Obstet Gynaecol; 1994 Sep; 101(9):782-6. PubMed ID: 7947527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down's syndrome screening with nuchal translucency.
    Nicolaides KH; Sebire NJ; Snijders RJ
    Lancet; 1997 Feb; 349(9049):438. PubMed ID: 9033507
    [No Abstract]   [Full Text] [Related]  

  • 12. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-trimester nuchal translucency and cardiac septal defects in fetuses with trisomy 21.
    Hyett JA; Moscoso G; Nicolaides KH
    Am J Obstet Gynecol; 1995 May; 172(5):1411-3. PubMed ID: 7755046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cut-off criteria for second-trimester nuchal skinfold thickness for prenatal detection of Down syndrome in a Thai population.
    Tannirandorn Y; Manotaya S; Uerpairojkit B; Tanawattanacharoen S; Charoenvidhya D; Phaosavasdi S
    Int J Gynaecol Obstet; 1999 May; 65(2):137-41. PubMed ID: 10405057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for Down's syndrome by fetal nuchal translucency measurement in a high-risk population.
    Pajkrt E; Mol BW; van Lith JM; Bleker OP; Bilardo CM
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):156-62. PubMed ID: 9793186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical dimensions of nuchal translucency screening.
    Chasen ST; Skupski DW
    Clin Perinatol; 2003 Mar; 30(1):95-102. PubMed ID: 12696788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrauterine lethality of trisomy 21 fetuses with increased nuchal translucency thickness.
    Hyett JA; Sebire NJ; Snijders RJ; Nicolaides KH
    Ultrasound Obstet Gynecol; 1996 Feb; 7(2):101-3. PubMed ID: 8776233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group.
    Snijders RJ; Noble P; Sebire N; Souka A; Nicolaides KH
    Lancet; 1998 Aug; 352(9125):343-6. PubMed ID: 9717920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuchal translucency and gestational age.
    Wald N; Rodeck C; Rudnicka A; Hackshaw A
    Prenat Diagn; 2004 Feb; 24(2):150-1. PubMed ID: 14974125
    [No Abstract]   [Full Text] [Related]  

  • 20. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency.
    Krantz DA; Hallahan TW; Orlandi F; Buchanan P; Larsen JW; Macri JN
    Obstet Gynecol; 2000 Aug; 96(2):207-13. PubMed ID: 10908764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.